Do you want to read an article? Please log in or register.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Breast Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Breast Cancer
A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)
Breast Cancer Res Treat.
Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Buono DL, Nathanson SD, Bovbjerg DH, Mandelblatt JS, Tsai WY, Jacobson JS, Hershman DL
doi: 10.1007/s10549-016-3855-3.
RECOMMENDED
Breast Cancer
Adjuvant chemotherapy in small node-negative triple-negative breast cancer
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer.
Steenbruggen TG, van Werkhoven E, van Ramshorst MS, Dezentjé VO, Kok M, Linn SC, Siesling S, Sonke GS
doi: 10.1016/j.ejca.2020.04.033.
Breast Cancer
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
J Clin Oncol.
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L
doi: 10.1200/JCO.19.00647.
RECOMMENDED
Breast Cancer
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
doi: 10.1200/JCO.19.00904.
RECOMMENDED
Breast Cancer
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
★ 3
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, Graff SL, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH
doi: 10.1200/JCO.20.02510.Visit the original publication at ncbi.nlm.nih.gov
Breast Cancer
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
JAMA.
Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG)
Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.
Breast Cancer Res Treat.
Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez-MacGregor M
doi: 10.1007/s10549-016-3815-y.
Breast Cancer
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
Br J Cancer.
Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V
doi: 10.1038/bjc.2017.158.